Last reviewed · How we verify
NCT07210268
Temporal Interference Methods for Addiction Treatment
NA trial testing TI-NDBS in Nicotine Use Disorder in 120 participants. Currently enrolling.
20 February 2027
Quick facts
| Lead sponsor | Indiana University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 22 January 2026 |
| Primary completion | 20 February 2027 |
| Estimated completion | 27 February 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- TI-NDBS
- Sham TI-NDBS
Conditions studied
- Nicotine Use Disorder — all drugs for Nicotine Use Disorder →
- Substance Use Disorders — all drugs for Substance Use Disorders →
Sponsor
Indiana University
Who can join
Adults 21 to 50, any sex, with Nicotine Use Disorder or Substance Use Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study is testing whether a new non-invasive brain stimulation method, called temporal interference (TI), can reduce nicotine cravings and usage in people who vape. TI delivers mild electrical currents to the scalp in a way that targets deep brain areas involved in addiction, without the need for surgery. In this randomized controlled trial, participants will be assigned to one of three groups: TI stimulation to the nucleus accumbens, TI stimulation to the anterior insula, or a placebo (sham) condition. Each participant will attend a single stimulation session after 8 hours of nicotine abstinence and will use a custom vape device that measures real-time nicotine inhalation. Craving levels will be reported during and after the session. The study aims to determine whether TI to the insula or nucleus accumbens is more effective at decreasing cravings and nicotine inhalation, and whether either is more effective than sham stimulation. For one week after the session, participants will use a smartphone app to track nicotine use and cravings. The primary hypothesis is that TI stimulation to deep brain regions will reduce both nicotine craving and actual use, immediately after stimulation and over the following week, compared to the sham condition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07210268
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nicotine Use Disorder
Currently open trials in the same condition.
- NCT06798324 — tDCS Plus Varenicline for Smoking Cessation · Phase 4 · recruiting
- NCT06695884 — Identify the Optimal TMS Pulse Protocol to Modulate Reward Activity · NA · recruiting
- NCT06544057 — Real-time eCounselling for Nicotine Addiction · NA · recruiting
- NCT05515354 — Smoking Cessation and Menstrual Cycle Phase · Phase 4 · recruiting
- NCT05181891 — Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking · Phase 2 · recruiting
Other Indiana University trials
Trials by the same sponsor.
- NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
- NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
- NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
- NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
- NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07210268 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indiana University
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07210268.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing